HMGB1 and neoplasm: Published data across a range of malignancies shows that necrosis is predictive of poor patient outcome3–8, that patients with increased expression of endogenous adjuvants such as calreticulin and HMGB1 in their tumor exhibit a worse prognosis than those with lower or absent expression9,10, and that blockade of the endogenous adjuvant HMGB1 improves immune control of tumors in preclinical models11.